Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Intermediate and high-risk clonal hematopoiesis in germline predisposition families

Sandra Novoa Jáuregui, Sara Torres-Esquius, Maria Gabarrós Subirà et al. Nov 03, 2025 pp. 2058-2058 10.1182/blood-2025-2058

Abstract INTRODUCTION Approximately 10% of adults diagnosed with myelodysplastic neoplasms (MDS) or acute myeloid leukem...

Risk stratification, prognostic factors, outcomes and quality of life assessment in patients with primary polycythemia

Reuban Roshy, Harriet Jeejo, Cecil Ross et al. Nov 03, 2025 pp. 7357-7357 10.1182/blood-2025-7357

Abstract Background: Polycythemia Vera(PV) is a chronic myeloproliferative neoplasm (MPN) characterized by clonal erythrocytosis. In the con...

Pregnancy outcomes among women with sickle cell disease: A propensity score-matched analysis approach using the national inpatient sample (2017-2022)

Benedict Amalraj, Mariana Marrero Castillo, Shidestini Martinez et al. Nov 03, 2025 pp. 6218-6218 10.1182/blood-2025-6218

Abstract Introduction: Pregnancies complicated by sickle cell disease (SCD) are associated with significant maternal and fetal risks. While...

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Rima M. Saliba, Jennifer Miatech, Jeremy Ramdial et al. Nov 03, 2025 pp. 5996-5996 10.1182/blood-2025-5996

Abstract Introduction. Results of our previous studies have suggested that the use of mycophenolate mofetil (MMF) for graft-versus-host dise...

Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance

Catherine Duane, Tony O'Grady, Sahin Sarihan et al. Nov 03, 2025 pp. 2175-2175 10.1182/blood-2025-2175

Abstract Background: Extramedullary disease (EMD) is an aggressive manifestation of multiple myeloma (MM) associated with inferior overall s...

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Alexandra Gomez-Arteaga, Rory Shallis, Mariam Nawas et al. Nov 03, 2025 pp. 1060-1060 10.1182/blood-2025-1060

Abstract Background: Acute myeloid leukemia (AML) with TP53 alteration (TP53alt), including deletion (TP53del) detected by cytogenetics (CG)...

Serum exo-miR584-5p mediates drug resistance in diffuse large B-cell lymphoma by upregulating the drug metabolism-CYP450 pathway, promoting high P450 expression, and remodling its intracellular localization.

Shuling Hou, Jinling Bo, Pan Chen et al. Nov 03, 2025 pp. 6823-6823 10.1182/blood-2025-6823

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Although stan...

Hematobot: Retrieval‑augmented large language model‑based assistants for therapy, toxicity and frailty management in multiple myeloma by the spanish society of hematology and hemotherapy (SEHH)

Marta Sonia Gonzalez Perez, Adrian Mosquera, Borja Puertas et al. Nov 03, 2025 pp. 6115-6115 10.1182/blood-2025-6115

Abstract Background Generative artificial intelligence (GenAI) powered by large language models (LLMs) and retrieval-aug...

Patient-derived amyloidogenic light chain triggers cardiovascular toxicity In Vivo and reveals ICAM-1 as a novel potential biomarker in patients with AL amyloidosis

Panagiota-Efstathia Nikolaou, Foteini Theodorakakou, Angelina Choustoulaki et al. Nov 03, 2025 pp. 5751-5751 10.1182/blood-2025-5751

Abstract Background and aims: In light chain (AL), the circulating immunoglobulin light chains (LCs) have been suggested to provoke cardioto...

Impact of angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARB) on tumor lysis syndrome, acute kidney injury, and rasburicase use in patients undergoing chemotherapy for hematologic malignancies

Haris Sohail, Saad Javaid, Emily Pack et al. Nov 03, 2025 pp. 4527-4527 10.1182/blood-2025-4527

Abstract Introduction Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are wide...

Asciminib versus second generation TKI in newly diagnosed chronic Phase chronic myeloid leukemia: A meta analysis

Noorul Hidhaya S, Tejaswini Mariappan, Haran Srinivasan Saravanan et al. Nov 03, 2025 pp. 7292-7292 10.1182/blood-2025-7292

Abstract Introduction: Chronic Myeloid Leukemia (CML) is categorized as a myeloproliferative neoplasm, with a global annual incidence of app...

Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis

Vikas Gupta, Jose Torregrosa, Georgios Vlasakakis et al. Nov 03, 2025 pp. 5580-5580 10.1182/blood-2025-5580

Abstract Introduction: Anemia is a prevalent and progressive manifestation of myelofibrosis (MF) with substantial impacts on patient quality...

Clinical outcomes in spliceosome-mutant myelodysplastic neoplasms and Acute Myeloid Leukemia

Ritika Walia, Kavya Sudireddy, Aviv Liani et al. Nov 03, 2025 pp. 7038-7038 10.1182/blood-2025-7038

Abstract Spliceosomes facilitate the removal of non-coding introns from precursor messenger RNA via a macromolecular complex to form mature...

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Pradipta Ray, Abood Okal, Miguel-Angel Perales et al. Nov 03, 2025 pp. 3549-3549 10.1182/blood-2025-3549

Abstract Introduction: The InflaMix (INFLAmmation MIXture) model classifies the disease of patients with R/R LBCL as inflamed or noninflamed...

Ectopic EBV infection in T cells following allogeneic hematopoietic stem cell transplantation: Clinical outcomes and immunological characterization

Zhifan Zhao, Lanping Xu, Xiangyu Zhao et al. Nov 03, 2025 pp. 2449-2449 10.1182/blood-2025-2449

Abstract Background: Epstein-Barr virus (EBV) infection is a common complication after allogeneic hematopoietic stem cell transplantation (a...

Epithelial growth factor like-7 (EGFL7) regulates hematopoiesis stem cell (HSC) activation via AP-1 suppression

Rohan Kulkarni, Yaphet Bustos, Alexander Rudich et al. Nov 03, 2025 pp. 209-209 10.1182/blood-2025-209

Abstract Limitations in the availability and expansion of hematopoietic stem cell (HSC) are a critical barrier for treating hematological di...

Bleeding disorder of unknown cause: Is there a role for expanded platelet testing?

Aishwarya Pradeep, Meera Sridharan, Dong Chen et al. Nov 03, 2025 pp. 311-311 10.1182/blood-2025-311

Abstract Introduction: Only 30% of patients (pts) presenting with abnormal bleeding symptoms receive a clear diagnosis,...

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Saad Usmani, Michał Mielnik, Aránzazu Alonso Alonso et al. Nov 03, 2025 pp. 5840-5840 10.1182/blood-2025-5840

Abstract Introduction: Belamaf is an antibody-drug conjugate approved in multiple countries as part of combination regimens for relapsed/ref...

Time-stratified risk of second primary solid malignancies among follicular lymphoma survivors in the United States

Merry Zhai, Matthew Matasar, Anand Shah et al. Nov 03, 2025 pp. 5371-5371 10.1182/blood-2025-5371

Abstract Introduction: Survivors of follicular lymphoma (FL) face an elevated risk of developing second primary malignancies (SPMs). The ris...

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP

Prokop Vodička, Patrick Reagan, Michal Masar et al. Nov 03, 2025 pp. 5448-5448 10.1182/blood-2025-5448

Abstract Introduction Although chemo-free regimens are increasingly used in elderly patients with large B-cell lymphoma (LBCL), most still r...

Treatment patterns and clinical outcomes in patients with lower-risk Myelodysplastic Syndromes rreated with first-line luspatercept: Findings from a medical record review in France and Germany

Christophe Willekens, Ahmed Hnoosh, Aylin Yucel et al. Nov 03, 2025 pp. 6412-6412 10.1182/blood-2025-6412

Abstract Background: In patients with lower-risk myelodysplastic syndrome (LR-MDS), luspatercept has demonstrated significant clinical benef...

CFP1 controls H3K4me3-mediated chromatin architecture to promote v(D)j recombination in early B cell development

Wanyu Bai, Yalin Yang, Yanan Zhao et al. Nov 03, 2025 pp. 629-629 10.1182/blood-2025-629

Abstract V(D)J recombination is a fundamental process in B lymphocyte development that generates a diverse immunoglobulin (Ig) repertoire th...

A FXIa-modified clot waveform analysis for estimation of factor VIII level and emicizumab concentration in hemophilia A

Oliver Königsbrügge, Atsuo Suzuki, Daniel Kraemmer et al. Nov 03, 2025 pp. 3065-3065 10.1182/blood-2025-3065

Abstract Background Hemophilia A treatment options include factor VIII (FVIII) substitution and non-factor therapies, li...

A single-center retrospective study of ixazomib-based regimens as maintenance therapy in newly diagnosed multiple myeloma

Yang Yang, Lin Luo, Zhongqing Li et al. Nov 03, 2025 pp. 7593-7593 10.1182/blood-2025-7593

Abstract Background Multiple myeloma (MM) remains incurable, and maintenance therapy is critical for sustaining remission and improving surv...

Community health worker contacts for high utilizer vs. other sickle cell patients in an adult sickle cell disease medical home

Andrea Burton, Shirley Johnson, Daniel Sop et al. Nov 03, 2025 pp. 4368-4368 10.1182/blood-2025-4368

Abstract Background Medical center-based Community Health Workers, also known as Patient Navigators (PNs), often increase patient engagement...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page